Ann: Phosphagenics Pain Program Update , page-51

I hear you neg- before this thread I thought oxy was the priority and was to go through a relatively quick phase 2/3, establishing POH and forcing big pharma to notice and think of the possibilities (cheque book in hand.)

Now it looks like the priority is not oxy but a 'pain portfolio.' This is all well and good but it disappoints me if this means parking oxy and waiting for every pain related patch to spend the next however many months or years going through the same hoops.

I would've thought if you had a product that you were confident could go all the way, you'd go hell for leather. Until today, I and some others here thought that was still the strategy.

I think the market reaction to today's 'brilliant' announcement echoes this sentiment. .